20221027104337.jpg&width=400&height=400)
A study led by Yale scientists, published April 25 in the journal Science Immunology, investigated the potential causes associated with T cell exclusion using a genome-wide screen of more than 1,000 human proteins.
20240208171546.png&width=400&height=400)
Memorial Sloan Kettering Cancer Center (MSK) today announced an innovative set of initiatives to support underserved communities in New York City who lack access to cancer screening and early detection. With critical support from longtime MSK Board Member Bruce Ratner, the Ratner Early Detection Initiative (REDI) draws from MSK’s deep experience in cancer science and discovery, community engagement, and compassionate patient care.
Cancer survivors and tennis legends Chris Evert and Martina Navratilova participated in a fireside-style chat with Robin Roberts on Wednesday, May 1, at The University of Texas MD Anderson Cancer Center’s signature event, A Conversation with a Living Legend ®, hosted at the Post Oak Hotel at Uptown Houston.
Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and others.
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Receiving a cancer diagnosis can be one of the most stressful, pivotal moments in an individual’s life. With May being Mental Health Awareness Month, Fred Hutch social psychologist and researcher Megan J. Shen, PhD, shares tips for coping with a cancer diagnosis and how patients and their caregivers can navigate appointments with their oncologists.
For most smokers, quitting on the first attempt is likely to be unsuccessful, but a new study from The University of Texas MD Anderson Cancer Center found patients were more likely to quit if their cessation regimen was altered and doses were increased. Researchers also found that varenicline, a cessation medication, was more effective than combined nicotine replacement therapy (CNRT), such as patches or lozenges.
A new UC Davis study finds biomarkers that could identify patients with 22q11.2 deletion syndrome who are more likely to develop schizophrenia.
Sharon Dent, Ph.D., professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been elected to the National Academy of Sciences (NAS). Dent is a global leader in the field of chromatin research whose foundational work has helped define the role of chromatin in cancer growth and development.
Connecticut Magazine released its “Top Doctors” issue today, listing some of the state’s best physicians, who provide exceptional care for patients. This year’s list includes 109 Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) physicians, a 35% increase in “Top Doctors” for SCH and YCC from last year.
International collaboration to improve cancer outcomes in Sub-Saharan Africa is working to update consensus harmonized guidelines on several key subjects in oncology, including how best to treat people with both cancer and HIV.
The University of Texas MD Anderson Cancer Center and the Pan American Health Organization (PAHO) today announced the signing of an agreement to strengthen cancer prevention and control initiatives across the Americas. The event took place in Washington, D.C., with leaders from both organizations.
Moffitt Cancer Center has launched a pioneering clinical trial for patients with late-stage non-small cell lung cancer whose disease has progressed following initial frontline standard of care immunotherapy that includes an immune checkpoint inhibitor alone or combined with chemotherapy.
MD Anderson and Replay today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New Drug (IND) application for PRAME TCR/IL-15 NK (SY-307), an engineered T cell receptor natural killer (TCR NK) cell therapy for relapsed/refractory myeloid malignancies.
A national study led by researchers at The University of Texas MD Anderson Cancer Center and The University of New Mexico (UNM) Comprehensive Cancer Center found major gaps in breast, cervical and colorectal cancer screening use in Federally Qualified Health Centers (FQHCs) in the US, relative to overall screening rates in the country.
A national study led by researchers at The University of Texas MD Anderson Cancer Center and The University of New Mexico (UNM) Comprehensive Cancer Center found major gaps in breast, cervical and colorectal cancer screening use in Federally Qualified Health Centers (FQHCs) in the U.S., relative to overall screening rates in the country.
The FDA announced 1 in 5 grocery store milk samples tested positive for bird flu. UC Davis experts explain the limits of the test and how to protect yourself from avian influenza.
The University of Texas MD Anderson Cancer Center and RUSH University System for Health today announced a partnership to create RUSH MD Anderson Cancer Center.
RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center, have announced that Eileen White, PhD, Deputy Director and Chief Scientific Officer at Rutgers Cancer Institute, has been elected as a member of the American Academy of Arts and Sciences.
The Foundation for the Accreditation of Cellular Therapy (FACT) has once again awarded Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital’s (RWJUH) Transplant and Cell Therapy Program accreditation under the FACT-JACIE International Standards for Hematopoietic Cellular Therapy
Cells constantly navigate a dynamic environment, facing ever-changing conditions and challenges. But how do cells swiftly adapt to these environmental fluctuations? A new Moffitt Cancer Center study, published in iScience, is answering that question by challenging our understanding of how cells function. A team of researchers suggests that cells possess a previously unknown information processing system that allows them to make rapid decisions independent of their genes.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A Ludwig Cancer Research study has discovered how a lipid molecule found at high levels within tumors undermines the anti-cancer immune response and compromises a recently approved immunotherapy known as adoptive cell therapy (ACT) using tumor infiltrating lymphocytes, or TIL-ACT.
Dana-Farber Cancer Institute nurse scientists and clinicians are presenting key studies and projects at the 49th annual Oncology Nursing Society (ONS) Congress on April 24-28, 2024, in Washington, D.C.
Socioeconomic factors are preventing some patients from accessing common treatment to stop progression of multiple myeloma.
New study by UC Davis researchers shows how pharmacies may provide crucial access to tobacco cessation tools that help people successfully quit smoking.
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have designed a new method for developing immunotherapy drugs using engineered peptides to elicit a natural immune response inside the body.
Kevin Haigis, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, has been named Fellow of the American Association for the Advancement of Science (AAAS). Election as an AAAS Fellow is a distinguished lifetime honor bestowed upon AAAS members by their peers.
A new Moffitt Cancer Center study published in the journal Immunity offers insight into how lung cancer cells evade the protective immune system, potentially opening a door for novel antibody-based immunotherapies. Their study centers on a molecule called Jagged2, which plays a primary role in fueling the aggressiveness and immune evasion capacity of lung cancer.
In recognition of their significant achievements in the realm of cancer care and research, four researchers at The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS). This prestigious distinction stands as one of the highest accolades within the scientific research community.
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—announces 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN’s mission to help all people with cancer to live better lives.
New research in the April 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network showcases the feasibility of improving early detection and prevention for pancreatic cancer.
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone.
MD Anderson and CureVac today announced a co-development and licensing agreement to develop novel mRNA-based cancer vaccines.
The National Comprehensive Cancer Network (NCCN) and the NCCN Foundation announce five winners for the 2024 NCCN Foundation Young Investigator Awards (YIA).
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
A new study from UC Davis Health's Emergency Medicine may lead to a reduction in inappropriate computed tomography use in injured children.
More than 1,700 oncology professionals attended National Comprehensive Cancer Network meeting in Orlando and online, featuring clinical and administrative updates for improving cancer care worldwide, plenary sessions on Lynch syndrome and drug shortages, plus nearly 200 poster abstracts with new research.
Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2024 show promising initial data for patients with lymphoma, gastric or gastroesophageal junction cancers, and specific molecularly selected tumors.
Cervical cancer, often caused by persistent human papillomavirus (HPV) infections, remains a public health challenge worldwide despite falling diagnoses related to the success of the HPV vaccine[GR1] in young adult women.
UC Davis Medical Center has become the first hospital in Western U.S. to perform a successful transcatheter tricuspid valve repair procedure with a groundbreaking catheter.
Obesity is associated with a higher risk of developing at least 13 types of cancer — and worse outcomes after diagnosis. But lung cancer seems to be an exception: Studies have shown that patients with a high body mass index (BMI) experience a lower risk of disease recurrence and longer survival after surgical treatment — an irregularity called “the obesity paradox.”
Combining the KRAS G12C inhibitor adagrasib with the anti-EGFR antibody cetuximab demonstrated promising anti-tumor effects in patients with KRAS G12C-mutated metastatic colorectal cancer (CRC), according to pooled results from the Phase I/II KRYSTAL-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in patients with homologous recombination repair (HRR)-deficient breast cancers, according to results from the Phase I/II PETRA trial led by researchers at The University of Texas MD Anderson Cancer Center.
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Jeffrey A. Drebin, MD, PhD, has been named President-Elect of the American Surgical Association (ASA) for 2024.
The National Comprehensive Cancer Network® (NCCN®)—a nonprofit devoted to patient care, research, and education—is announcing the election of Matt Kalaycio, MD, FACP, as Chair of the Board of Directors, with Christopher H. Lieu, MD, elected as Vice-Chair, succeeding Dr. Kalaycio in the position he has held since 2022.
Researchers from The University of Texas MD Anderson Cancer Center presented encouraging findings today from two clinical trials in a plenary session highlighting advances in novel immunotherapy approaches at the American Association for Cancer Research (AACR) Annual Meeting 2024.
In a small, investigator-initiated phase 2 study by Dana-Farber Cancer Institute investigators, a novel combination of an antibody-drug conjugate and an immune checkpoint inhibitor showed notable activity in pre-treated patients with a difficult-to-treat form of endometrial cancer. In this study, tumors were reduced in six out of 16 patients treated with the combination, including one case in which the cancer disappeared.
Numerous studies conducted by researchers at Dana-Farber Cancer Institute show promising results for patients with endometrial, lung, breast, prostate, and colorectal cancers.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
